BioNTech SE (0A3M)
LSE
117.50
+7.00 (+6.33%)
Closed
Aug 21, 2026
Day's Range
110.14120.35
52 wk Range
79.51123.69
Financial Statements - 0A3M - BioNTech SE
Revenue
2.86B▲ 4.3%
Net Income
-1.13B▼ 70.8%Net Margin -39.6%
EBITDA
-256.30M▲ 13.9%
Free Cash Flow
-293.00M▼ 19.8%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 2.86B | 2.75B | 3.81B | 17.31B | 18.97B | 482.30M |
| Cost of Goods | 641.80M | 541.30M | 599.80M | 2.99B | 2.91B | 59.30M |
| Gross Profit | 2.22B | 2.20B | 3.21B | 14.31B | 16.06B | 423M |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -640.70M | -595.70M | 904.20M | 12.30B | 14.92B | -82.40M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -397.50M | -69.40M | -67.80M | 620.70M | 145.10M | -59.90M |
| Pre Tax Income | -1.05B | -677.70M | 1.18B | 12.95B | 15.04B | -145.80M |
| Income Tax | 85.30M | -12.40M | 255.80M | 3.51B | 4.75B | -161M |
| Net Income | -1.13B | -665.30M | 930.30M | 9.43B | 10.29B | 15.20M |
| EPS Basic | -4.7 | -2.77 | 3.87 | 38.78 | 42.18 | 0.06 |
| EPS Diluted | -4.7 | -2.77 | 3.83 | 37.77 | 39.63 | 0.06 |
| Basic Shares Outstanding | 241.70M | 240.18M | 222.21M | 233.72M | 234.41M | 243.35M |
| Diluted Shares Outstanding | 241.70M | 240.18M | 222.21M | 233.72M | 234.41M | 243.35M |
| Ebit | -1.03B | -665.10M | 904.20M | 12.30B | 14.92B | -143.80M |
| Ebitda | -256.30M | -297.70M | 1.15B | 11.80B | 14.85B | -45.20M |
| Net Income Continuous Operations | -1.05B | -677.70M | 1.18B | 12.95B | 15.04B | -145.80M |
| Minority Interests | - | - | - | - | 0 | 0 |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
